Viatris Inc. announced its financial results for the fourth quarter and full year 2024, meeting its guidance for total revenues, adjusted EBITDA, and adjusted EPS. For the full year 2024, total revenues reached $14.7 billion, adjusted EBITDA was $4.7 billion, and adjusted EPS stood at $2.65. The company exceeded its free cash flow guidance, generating $2.0 billion, and reported $582 million in new product revenues.
In 2024, Viatris returned $825 million in capital to shareholders and repaid $3.7 billion of debt, successfully achieving its long-term gross leverage target of 2.9x. For the fourth quarter of 2024, total net sales were $3,515.4 million, an 8% reported decrease, but a 1% increase on a divestiture-adjusted operational basis. The company reported a U.S. GAAP net loss of $(516.5) million and adjusted EPS of $0.54.
Looking ahead, Viatris provided its 2025 financial guidance, which includes an anticipated negative impact of approximately $500 million to total revenues and $385 million to adjusted EBITDA due to the Indore facility warning letter and import alert. The company forecasts 2025 total revenues between $13.5 billion and $14.0 billion, adjusted EBITDA between $3.9 billion and $4.2 billion, and adjusted EPS between $2.12 and $2.26.
Free cash flow for 2025 is projected to be between $1.8 billion and $2.2 billion. Viatris stated that remediation efforts at the Indore manufacturing facility are more than halfway complete, with a request for FDA reinspection expected in a few months. The company is also prioritizing capital return in 2025, targeting $500 million to $650 million in share repurchases.
Furthermore, Viatris expects six Phase 3 data readouts and important late-stage development milestones for innovative assets like selatogrel, cenerimod, and sotagliflozin in 2025. An enterprise-wide initiative has also commenced to review its global infrastructure and identify additional cost savings, aiming to streamline operations post-divestitures.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.